Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260378 | 0.87 | CNR1 (0.49) | HSD11B1CNR1 | |
| SCHEMBL2570109 | 0.81 | ESR1 (0.51) | HSD11B1CNR1 | |
| SCHEMBL1258893 | 0.78 | MARS1 (0.52) | CNR1 | |
| SCHEMBL1260019 | 0.77 | CNR1 (0.68) | CNR1 | |
| SCHEMBL4074362 | 0.76 | CNR1 (0.67) | CNR1 | |
| SCHEMBL2901352 | 0.76 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL1986082 | 0.75 | MAPT (0.47) | — | |
| SCHEMBL1260411 | 0.75 | CNR1 (0.43) | HSD11B1CNR1 | |
| SCHEMBL1260541 | 0.75 | CNR1 (0.60) | CNR1 | |
| SCHEMBL19478192 | 0.75 | DPP4 (0.47) | HSD11B1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899298-B1 | DERIVATIVES OF 4,5-DIARYLPYRROLE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-08-18 | — | — | EP | disclosed |
| US-7618995-B2 | Derivatives of 4,5-diarylpyrrole, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2009-11-17 | — | — | US | disclosed |
| US-20080176924-A1 | antiinflammatory agents; cannabinoid receptor modulators; obesity; antagonists; N-((5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-methyl-1H-pyrrol-2-yl)methyl)-4-(trifluoromethyl)benzamide | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176924-A1 | antiinflammatory agents; cannabinoid receptor modulators; obesity; antagonists; N-((5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-methyl-1H-pyrrol-2-yl)methyl)-4-(trifluoromethyl)benzamide | CNR1, CNR2, GPR119 | HSD11B1 1959/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.